Vivarelli M, Gibson K, Sinha A, Boyer O. Childhood nephrotic syndrome. The Lancet 2023;402:809–24. DOI: https://doi.org/10.1016/S0140-6736(23)01051-6

Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. The Lancet 2018;392:61–74. DOI: https://doi.org/10.1016/S0140-6736(18)30536-1

Ehren R, Benz MR, Brinkkötter PT, Dötsch J, Eberl WR, Gellermann J, et al. Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy - short version of the updated German best practice guideline (S2e) — AWMF register no. 166-001, 6/2020. Pediatr Nephrol 2021;36:2971–85. DOI: https://doi.org/10.1007/s00467-021-05135-3

Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri GM. Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: A randomized clinical trial. JAMA Pediatr 2021;175:631–2. DOI: https://doi.org/10.1001/jamapediatrics.2020.6150

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. DOI: https://doi.org/10.1002/9781119536604

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372. DOI: https://doi.org/10.1136/BMJ.N71

Sterne JAC, Savovi? J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:I4898. DOI: https://doi.org/10.1136/bmj.l4898

McKenzie J, Brennan S. Chapter 12: Synthesizing and presenting findings using other methods. Cochrane, 2024 [updated 2019 Oct 31; cited 2024 Feb 10]. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Cochrane Handb. Syst. Rev. Interv. version 6.5. Available from: https://training.cochrane.org/handbook/

Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: A superiority randomized trial. J Am Soc Nephrol JASN 2021;32:2652–63. DOI: https://doi.org/10.1681/ASN.2021040561

Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea. Medicine (Baltimore) 2018;97:e13157. DOI: https://doi.org/10.1097/MD.0000000000013157

Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang S-Y, Henique C, et al. NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun 2018;88:91–102. DOI: https://doi.org/10.1016/j.jaut.2017.10.006

Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol JASN 2012;23:1117–24. DOI: https://doi.org/10.1681/ASN.2011080775

Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol CJASN 2011;6:1308–15. DOI: https://doi.org/10.2215/CJN.09421010

Hanif N, Anwer F. Rituximab. StatPearls [Internet]. 2023 Sep 26 [cited 2024 Feb 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564374/

Chan EY-H, Yap DY-H, Colucci M, Ma AL-T, Parekh RS, Tullus K. Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol CJASN 2023;18:533–48. DOI: https://doi.org/10.2215/CJN.08570722

Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: A systematic review and meta-analysis. BMC Nephrol 2020;21. DOI: https://doi.org/10.1186/s12882-020-01797-7

Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, et al. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? Autoimmun Rev 2020;19:102671. DOI: https://doi.org/10.1016/j.autrev.2020.102671

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021;100:S1–276. DOI: https://doi.org/10.1016/j.kint.2021.05.021

Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients’ management. Nat Rev Nephrol 2013;9:154–69. DOI: https://doi.org/10.1038/nrneph.2012.289

Chaki A, Rahman F, Arju J, Al Mamun A-, Jesmin T, Huque SS, et al. Rituximab in steroid resistant nephrotic syndrome. Paediatr Indones 2019;59:175–82. DOI: https://doi.org/10.14238/pi59.4.2019.175-82

Kallash M, Smoyer WE, Mahan JD. Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr 2019;7:178. DOI: https://doi.org/10.3389/fped.2019.00178

Maxted AP, Dalrymple RA, Chisholm D, McColl J, Tse Y, Christian MT, et al. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol 2019;34:855–63. DOI: https://doi.org/10.1007/s00467-018-4172-3

Qader MA, Vivarelli M. Children with steroid dependent nephrotic syndrome: Rituximab or tacrolimus? It’s all in the timing. Kidney Int Rep 2023;8:1708–10. DOI: https://doi.org/10.1016/j.ekir.2023.07.016

Basu B, Preussler S, Sander A, Mahapatra TKS, Schaefer F. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome. BMC Nephrol 2020;21:520. DOI: https://doi.org/10.1186/s12882-020-02153-5

Specialised Commissioning Team, NHS England. Clinical commissioning policy: Rituximab for the treatment of relapsing steroid sensitive nephrotic syndrome. United Kingdom: NHS England; 2015 [cited 2024 Feb 15]. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/07/Rituximab-for-the-treatment-of-relapsing-steroid-sensitive-nephrotic-syndrome.pdf

Takura T, Takei T, Nitta K. Cost-effectiveness of administering rituximab for steroid-dependent nephrotic syndrome and frequently relapsing nephrotic syndrome: A preliminary study in Japan. Sci Rep 2017;7:46036. DOI: https://doi.org/10.1038/srep46036

Tan L, Li S, Yang H, Zou Q, Wan J, Li Q. Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019;98:e15927. DOI: https://doi.org/10.1097/MD.0000000000015927